Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab (vol 28, pg 492, 2017)

被引：0
|
作者：
Elewski, B.
Puig, L.
Mordin, M.
Gilloteau, I
Sherif, B.
Fox, T.
Gnanasakthy, A.
Papavassilis, C.
Strober, B.
机构：
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2017年 / 28卷 / 06期
关键词：
D O I：
10.1080/09546634.2017.1307464
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：571 / 571
页数：1
相关论文
共 11 条
  • [1] Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab
    Elewski, Boni E.
    Puig, Lluis
    Mordin, Margaret
    Gilloteau, Isabelle
    Sherif, Bintu
    Fox, Todd
    Gnanasakthy, Ari
    Papavassilis, Charis
    Strober, Bruce E.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (06) : 492 - 499
  • [2] Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response
    Sinclair, R.
    McLeod, L.
    Mallya, U. G.
    Fox, T.
    Strober, B.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 68 - 68
  • [3] Improvements in health-related quality of life and symptoms of depression with tofacitinib: Results from two randomized phase 3 studies in patients with moderate to severe psoriasis
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Bundy, Christine
    Korman, Neil J.
    Lan, Shuping
    Robertson, Deborah
    Tatulych, Svitlana
    Tallman, Anna
    Kaur, Mandeep
    Mamolo, Carla
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [4] Application of the statistical method to convert published PASI 50/75/90/100 into absolute PASI response rate in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab based on data from two pivotal phase 3 studies (reSURFACE 1/2)
    Dykukha, Igor
    Schoenenberger, Andreu
    Kasujee, Ismail
    Mrowietz, Ulrich
    Vonthein, Reinhard
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB79 - AB79
  • [5] Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2
    Dykukha, Igor
    Schoenenberger, Andreu
    Kasujee, Ismail
    Mrowietz, Ulrich
    Vonthein, Reinhard
    [J]. DERMATOLOGY, 2022, 238 (05) : 910 - 918
  • [6] Bimekizumab early treatment response translates into cumulative health-related quality of life benefits in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Rubel, Diana
    Gordon, Kenneth B.
    Sebastian, Michael
    Feldman, Steven R.
    Eusebi, Paolo
    Wixted, Krista
    Madden, Cynthia
    Gomez, Natalie Nunez
    Ciaravino, Valerie
    Radtke, Marc
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 19 - 20
  • [7] Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2) (vol 13, pg 315, 2023)
    Gisondi, Paolo
    Gottlieb, Alice B.
    Elewski, Boni
    Augustin, Matthias
    McBride, Sandy
    Tsai, Tsen-Fang
    de la Loge, Christine
    Fierens, Frederik
    Lopez Pinto, Jose M.
    Tilt, Nicola
    Lebwohl, Mark
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (06) : 1389 - 1390
  • [8] Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
    Gordon, Kenneth B.
    Sebastian, Michael
    Feldman, Steven R.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
  • [9] Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
    Gisondi, Paolo
    Gottlieb, Alice B. B.
    Elewski, Boni
    Augustin, Matthias
    McBride, Sandy
    Tsai, Tsen-Fang
    de la Loge, Christine
    Fierens, Frederik
    Lopez Pinto, Jose M.
    Tilt, Nicola
    Lebwohl, Mark
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (01) : 315 - 328
  • [10] Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
    Paolo Gisondi
    Alice B. Gottlieb
    Boni Elewski
    Matthias Augustin
    Sandy McBride
    Tsen-Fang Tsai
    Christine de la Loge
    Frederik Fierens
    José M. López Pinto
    Nicola Tilt
    Mark Lebwohl
    [J]. Dermatology and Therapy, 2023, 13 : 1389 - 1390
12